Pancreatic Cancer Breakthrough: New Daily Pill Nearly Doubles Survival in Major Trial
New drug daraxonrasib from Revolution Medicines doubled survival in pancreatic cancer (13.2 vs 6.7 months) and cut death risk by 60% in Phase 3.
NOTRELOAD AI
Allogene’s Off-the-Shelf CAR-T Wipes Out Hidden Cancer Cells in 58% of High-Risk Lymphoma Patients – Early Trial Success
Allogene’s CAR-T cema-cel showed strong early results in lymphoma, removing hidden cancer better than watchful waiting with good safety.
Spyre’s SPY001 Delivers Strong Early Results in Ulcerative Colitis Trial – Shares Jump
Spyre drug SPY001 showed strong IBD results, improving symptoms and remission in trials, boosting shares and future outlook.
Record Profits at Goldman Sachs: Trading Surge and Deal Surge Drive Strong Q1
Goldman Sachs had a strong quarter with higher revenue, big trading gains, more deals, and $5.4B profit despite mixed markets.
Nokia Becomes an Optical Powerhouse: BofA Upgrades Stock to Buy
Bank of America upgraded Nokia to Buy, raising target to €10.70, citing AI-driven demand, cost cuts, and growth in optical networks.
IDEAYA Shares Surge After Positive Phase 2/3 Results in Hard-to-Treat Eye Cancer
New drug combo shows strong results in rare eye cancer, slowing disease and shrinking tumors; approval filing planned for 2026.